Antimalarial medicine and their metabolites are potent Zika virus inhibitors

2^nd World Congress Virology and Infectious disease
Date: September 3-4, 2019
Venue: London, UK
URL:  https://bit.ly/2q62wrS  

Antimalarial medicine and their metabolites are potent Zika virus inhibitors

Studies aimed at repurposing existing drugs discovered that some antimalarial compounds possess anti‐Zika virus (anti‐ZIKV) activity.

Here, we tend to any tested 14 further antimalarial medication and their metabolites or analogs for anti‐ZIKV activity employing a makeup screening approach.

We tend to know four compounds with variable anti‐ZIKV activity, together with a matter of amodiaquine termed desethylamodiaquine (DAQ) and N‐desethylchloroquine (DECQ), a matter of chloroquine, that each exhibited low micromolar effective concentrations against 3 completely different ZIKV strains.

2 alternative compounds termed dihydroartemisinin (DHA) and Quinora (QD) exhibited solely partial inhibition of ZIKV replication.

Characterization of the repressing mechanisms of DAQ and DECQ showed that each medication target the entry step similarly as postentry events of the infective agent replication cycle.

These hits represent enticing beginning points for future optimization of the latest anti‐ZIKV drug candidates derived from antimalarial drugs and their analogs.

To know more about virology and infectious disease, attend an event on Viral Immunology at Virology Summit

Contact details
Clara Charlotte
Program Manager | Virology 2019
Email:virology@microbioconferences.com

Phone: +44 20 3769 1755